Decreased variability in the site-specific results during participation in the External Quality Assurance Program Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

The NIAID DAIDS-sponsored External Quality Assurance Program Oversight Laboratory (EQAPOL) manages an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) external proficiency program. The ELISpot program evaluates the accuracy and variability of results across laboratories. The variability in the program is quantified via the dispersion, which is the ratio of the variance over the mean of the background-corrected spot-forming cells (SFC) replicates obtained under stimulation with different peptide pools (CMV, CEF).

Accounting for the uncertainty due to chemicals below the detection limit in mixture analysis.

Simultaneous exposure to a mixture of chemicals over a lifetime may increase an individual's risk of disease to a greater extent than individual exposures. Researchers have used weighted quantile sum (WQS) regression to estimate the effect of multiple exposures in a manner that identifies the important (etiologically relevant) components in the mixture. However, complications arise when an experimental apparatus detects concentrations for each chemical with a different detection limit.